Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cemiplimab by Regeneron Pharmaceuticals for Natural Killer Cell Lymphomas: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Natural Killer Cell Lymphomas. According to...
Cemiplimab by Regeneron Pharmaceuticals for T-Cell Lymphomas: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...
Cemiplimab by Regeneron Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Mibavademab by Regeneron Pharmaceuticals for Acquired Generalized Lipodystrophy (Lawrence Syndrome): Likelihood of Approval
Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acquired Generalized Lipodystrophy (Lawrence Syndrome). According...
Mibavademab by Regeneron Pharmaceuticals for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome): Likelihood of Approval
Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome). According...
Cemiplimab by Regeneron Pharmaceuticals for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData,...
Cemiplimab by Regeneron Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Odronextamab by Regeneron Pharmaceuticals for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma. According to...
Odronextamab by Regeneron Pharmaceuticals for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Dupilumab by Regeneron Pharmaceuticals for Gastritis: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastritis. According to GlobalData, Phase III...
Dupilumab by Regeneron Pharmaceuticals for Gastroenteritis: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastroenteritis. According to GlobalData, Phase III...
Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...
Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...
Odronextamab by Regeneron Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Cemiplimab by Regeneron Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...
Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...
REGN-9933 by Regeneron Pharmaceuticals for Venous Thromboembolism: Likelihood of Approval
REGN-9933 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Venous Thromboembolism. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Fianlimab?
Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Linvoseltamab?
Linvoseltamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Pre-Registration program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma....